Cite
HARVARD Citation
Hettema, W. et al. (2017). A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert opinion on investigational drugs. pp. 889-896. [Online].